Last data update: May 06, 2024. (Total: 46732 publications since 2009)
Records 1-3 (of 3 Records) |
Query Trace: Santoli J[original query] |
---|
U.S. COVID-19 vaccine distribution strategies, systems, performance, and lessons learned, December 2020 - May 2023
Duggar C , Santoli JM , Noblit C , Moore LB , El Kalach R , Bridges CB . Vaccine 2024 During December 2020 through May 2023, the Centers for Disease Control and Prevention's (CDC) Immunization Services Division supported and executed the largest vaccine distribution effort in U.S. history, delivering nearly one billion doses of COVID-19 vaccine to vaccine providers in all 50 states, District of Columbia, Puerto Rico, Virgin Islands, Guam, Federated States of Micronesia, American Samoa, Marshall Islands, Northern Mariana Islands, and Palau. While existing infrastructure, ordering, and distribution mechanisms were in place from the Vaccines for Children Program (VFC) and experience had been gained during the 2009 H1N1 pandemic and incorporated into influenza vaccination pandemic planning, the scale and complexity of the national mobilization against a novel coronavirus resulted in many previously unforeseen challenges, particularly related to transporting and storing the majority of the U.S. COVID-19 vaccine at frozen and ultra-cold temperatures. This article describes the infrastructure supporting the distribution of U.S. government-purchased COVID-19 vaccines that was in place pre-pandemic, and the infrastructure, processes, and communications efforts developed to support the heightened demands of the COVID-19 vaccination program, and describes lessons learned. |
Preparing for the 2020-2021 Influenza Season.
Uyeki TM , Santoli J , Jernigan DB . JAMA 2020 324 (22) 2318-2319 As health care systems across the US are experiencing or preparing for surges in individuals with coronavirus disease 2019 (COVID-19) this fall and winter, the potential for cocirculation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses poses added challenges for clinicians and public health. Recent reports suggest that influenza activity can be influenced substantially by nonpharmaceutical measures implemented to control the spread of SARS-CoV-2 (eg, use of face masks, social distancing, restrictions on public gatherings, travel restrictions) and other factors influenced by the COVID-19 pandemic (eg, reduced domestic and international travel). In early spring of 2020, sharp declines in influenza activity coincided with implementation of SARS-CoV-2 control measures in the US.1 |
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration - United States, 2020.
Santoli JM , Lindley MC , DeSilva MB , Kharbanda EO , Daley MF , Galloway L , Gee J , Glover M , Herring B , Kang Y , Lucas P , Noblit C , Tropper J , Vogt T , Weintraub E . MMWR Morb Mortal Wkly Rep 2020 69 (19) 591-593 On March 13, 2020, the president of the United States declared a national emergency in response to the coronavirus disease 2019 (COVID-19) pandemic (1). With reports of laboratory-confirmed cases in all 50 states by that time (2), disruptions were anticipated in the U.S. health care system's ability to continue providing routine preventive and other nonemergency care. In addition, many states and localities issued shelter-in-place or stay-at-home orders to reduce the spread of COVID-19, limiting movement outside the home to essential activities (3). On March 24, CDC posted guidance emphasizing the importance of routine well child care and immunization, particularly for children aged </=24 months, when many childhood vaccines are recommended. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure